At a glance
ClinicalIndex Comparison RecordN/ACompleted· 481 enrolled
Drug / intervention
Axitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Panel-Based Chart Review Study to Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving First-Line Axitinib in Combination With Immune-Oncology Drugs for the Treatment of Advanced Renal Cell Carcinoma
In Brief
An observational study evaluating Axitinib, Avelumab, and 1 other intervention for Renal Cell Carcinoma. Completed, enrolled 481 participants across 1 site.
Detailed Summary
To assess how dose reductions or treatment interruptions related to axitinib can be implemented to manage and resolve adverse events occurring among patients with advanced renal cell carcinoma treated with first-line axitinib in combination with avelumab or pembrolizumab
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartFeb 2021
Primary CompletionApr 2021
TodayJul 2026
First PostedDec 24, 2020
Enrollment StartFeb 24, 2021
Primary CompletionApr 5, 2021
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 5.5 years ago
Interventions
Axitinibdrug
Inlyta, axitinib
Avelumabdrug
Avelumab, Bavencio
Pembrolizumabdrug
Pembrolizumab, Keytruda